Recent studies have revealed an association between the dysregulation of the gut microbiome and dementia. However, whether this dysregulation is associated with mild cognitive impairment (Mci), an early stage of cognitive decline, in patients without dementia remains unclear. We performed a cross-sectional analysis to determine the association between the gut microbiome and Mci. Data, including patient demographics, risk factors, cognitive function, and brain imaging, were collected. the gut microbiome was assessed through terminal restriction fragment length polymorphism analysis. Multivariable logistic regression models were used to identify factors independently associated with MCI. Graphical modelling was used to illustrate mutual associations between MCI and identified factors. We analysed 82 patients, 61 of whom exhibited MCI. Patients with MCI had a higher prevalence of Bacteroides. furthermore, patients with more Bacteroides were more likely to present with white matter hyperintensity and high voxel-based specific regional analysis system for Alzheimer's Disease (VSRAD) scores, indicating cortical and hippocampal atrophy. A multivariable logistic regression analysis revealed that a greater prevalence of Bacteroides was independently associated with Mci. Graphical modelling also showed a close association between Bacteroides and Mci. in conclusion, an increased prevalence of Bacteroides is independently associated with the presence of Mci in patients without dementia.
Results
patient characteristics. We previously analysed 128 patients in the Gimlet study. Of these, 46 were excluded: 34 had dementia, and 12 provided an insufficient quantity of faecal samples. Therefore, we analysed the remaining 82 eligible patients without dementia for this sub-analysis (female: 52.4%; mean age: 73.9 ± 8.1 years; mean Mini-Mental State Examination [MMSE] score: 27). Patients were stratified according to their levels of cognitive function and their enterotypes: 61 (74.4%) were classified as MCI, and 21 were classified as NC (Tables 1-3); 38 were enterotype I (46.3%), 5 were enterotype II (6.1%), and 39 were enterotype III (47.6%).
Mci vs. nc. Compared with NC patients, those with MCI were older (MCI vs. NC: median years, 77 vs. 69, P < 0.001), had a higher prevalence of hypertension (63.9% vs. 38 .1%, P = 0.045) and were more likely to present with indications of cerebral small vessel disease (SVD), such as white matter hypersensitivity (WMH) (34.4% vs. 4.8%, P = 0.009), and impaired instrumental ADL scores (44.3% vs. 9.5%, P = 0.004). Additionally, patients with MCI had higher scores on the Dementia Behaviour Disturbance Scale (DBDS), Zarit Caregiver Burden Interview (ZBI), and voxel-based specific regional analysis system for Alzheimer's Disease (VSRAD) (median scores: 10 vs. 2, P < 0.001; 11 vs. 6, P = 0.043; and 0.96 vs. 0.52, P = 0.010, respectively), as well as lower Geriatric Depression Scale (GDS) scores (median score: 2 vs. 4, P = 0.032) and reduced cognitive function, as demonstrated by lower comparison by enterotype. As described, we stratified the enrolled patients according to the enterotypes of their microbes and performed the following comparisons: enterotype I vs. non-enterotype I and and enterotype III vs. non-enterotype III (Tables S1 and S2, respectively). When compared with non-enterotype I patients, patients with increased levels of enterotype I microbes were more likely to exhibit a higher prevalence of cerebral SVD components (enterotype I vs. non-enterotype I: silent lacunar infarcts [SLI], 5.3% vs. 2.3%, P = 0.594; WMH, 39.5% vs. 15.9%, P = 0.024; cerebral microbleeds [CMB], 23.7% vs. 11.4%, P = 0.155; and cortical superficial siderosis [CSS], 7.9% vs. 2.3%, P = 0.332), higher VSRAD scores (median score, 0.96 vs. 0.80, P = 0.112), lower global cognitive function (median score, MMSE, 25 vs. 27, P = 0.046; CDR-SB, 2 vs. 0.5, P = 0.002), and impaired memory function (LM-WMSR I, 8 vs. 11, P = 0.134; and LM-WMSR II, 2 vs. 5, P = 0.041). No significant differences were observed for demographics or risk factors (e.g., mean age, 77 vs. 75, P = 0.145) between enterotype I patients and non-enterotype I patients (Table S1 ). In contrast, compared with non-enterotype III patients, patients with more enterotype III microbes had a lower prevalence of cerebral SVD components (enterotype III vs. non-enterotype III, SLI, 2.6% vs. 4.7%, P = 1.000; WMH, 15.4% vs. 37.2%, P = 0.045; CMB, 10.3% vs. 23.3%, P = 0.148; and CSS, 2.6% vs. 7.0%, P = 0.617) but were more likely to have low VSRAD scores (median score, 0.69 vs. 1.00, P = 0.048) and increased global cognitive function (median score, MMSE, 27 vs. 25, P = 0.071; and CDR-SB, 0.5 vs. 2, P = 0.007) (Table S2 ). Although there appeared to be significant differences regarding the prevalence of hypertension and alcohol consumption between enterotype III and non-enterotype III patients, no significant differences were observed for the Firmicutes/Bacteroidetes (F/B) ratio (Tables S3 and S4 ). No significant differences were observed for enterotypes between males and females (Table S5 ).
Multivariable analysis.
Multivariable logistic regression analyses were performed to identify factors that are independently associated with MCI. Due to the small number of patients, these analyses were performed in step-by-step increments of the number of independent variables: model 1 (adjusted for age, sex, education year, apolipoprotein E [ApoE] ε4 carrier, enterotype, and F/B ratio), model 2 (stepwise adjusted for model 1 and prevalence of risk factors), and model 3 (stepwise adjusted for model 2, magnetic resonance imaging [MRI] findings, and single photon emission computed tomography [SPECT] findings). Multivariable logistic regression analyses revealed that increased levels of enterotype I microbes was associated with the presence of MCI, independent of age, sex, education years, ApoE ε4, traditional risk factors, and brain imaging (model 1: odds ratio [OR 10.2], 95% confidence interval [95% CI], 2.23-62.7, P = 0.002; model 2: OR 5.95, 95% CI, 1.61-28.2, P = 0.006; and model 3: OR 5.36, 95% CI, 1.30-28.7, P = 0.019; Table 4 ). Conversely, enterotype III was independently associated with the presence of MCI (model 1: OR 0.09, 95% CI, 0.02-0.42, P = 0.002; model 2: OR 0.19, 95% CI, 0.05-0.65, P = 0.008; and model 3: OR 0.19, 95% CI, 0.05-0.65, P = 0.008) ( Table 5 ).
Graphical modelling. Graphical modelling was performed to visualize the mutual associations among factors used in the multivariable logistic regression analyses. Accordingly, modelling showed that the presence of MCI was more likely to be associated with age and was equally associated with ApoE ε4 and enterotype I. Enterotype I was closely associated with the presence of MCI when compared with the other factors. Furthermore, a close association between CMB and WMH was shown by this modelling (Fig. 1 ).
Discussion
The primary finding of our present study was that the increased prevalence of Bacteroides, defined as enterotype I, was independently associated with the presence of MCI in patients without dementia. Specifically, patients with an increased prevalence of Bacteroides were more likely to have lower global cognitive function (indicated by MMSE and CDR scores) and impaired memory dysfunction (indicated by logical memory subtests) compared with non-enterotype I patients, although there were no significant differences in demographics and risk factors, such as age, sex, and hypertension.
Recent studies have reported controversial findings regarding an association between the gut microbiome and dementia. For example, previous reports have shown both decreased 5,6 and increased 7 proportions of Bacteroides 7 , speculated that LPS is the component of Bacteroidetes that potentiates systemic inflammation and amyloid fibrillogenesis, ultimately resulting in amyloid deposition. Furthermore, Zhao and Lukiw et al., also reported that microbiome-derived LPS was enriched in the perinuclear region of the AD brain 14 , whereas LPS was detected in the hippocampus of patients with AD 9 . Our findings are consistent with these studies because our patients with more Bacteroidetes had lower logical memory subtest scores, indicating impaired memory function. Table 4 .
The mechanism through which the gut microbiome affects human cognitive functions remains unknown, although animal studies strongly implicate the gut microbiome as a key regulator of the brain and behaviour 15 . The functional pathways through which the gut microbiome communicates with the brain, also known as gut-microbiome-brain cross-talk, is a bidirectional, functional communication network between microbes and the brain that comprises neuroendocrine, neural, and neuroimmune signalling pathways 16 . Explicitly, three hypothesis have been proposed: (1) a circulation pathway, indicating the transportation of microbial metabolites, toxins, and pro-inflammatory factors; (2) a neuroendocrine pathway, indicating the activation of neuroendocrine cells that can be attributed to microbial metabolites; and (3) a neural pathway, indicating an interaction between the gut microbiome and the autonomic nervous system. This previous report also showed that an increase in the abundance of a pro-inflammatory gut microbiome taxon and a reduction in the abundance of an anti-inflammatory taxon may be associated with a peripheral inflammatory state in patients with cognitive impairments and brain amyloidosis 17 . Another report describing the gut-brain module analysis of faecal metagenomes identified the microbial synthesis of metabolites and suggested a potential role for these metabolites in the onset of depression 18 .
At present, we do not have sufficient data to identify the underlying mechanism that mediates the association between the gut microbiome and cognitive impairment. However, potential differences regarding the presence of WMH may represent supporting evidence that cerebral SVD acts as an intermediate between cognitive impairment and the gut microbiome. Likewise, Ong et al., reported that alterations in brain structure, as assessed by diffusion tensor imaging of MRI scans, were associated with the gut microbiome 19 , suggesting there may be a definite and direct relationship between the gut microbiome and the brain parenchyma. Further studies examining the association between cerebral SVD and gut microbiome metabolites in the Gimlet study cohort will shed light on this issue.
Here, we found other interesting findings. There was an independent association between WMH and the gut microbiome, although other components of cerebral SVD, such as SLI and CMB, did not show such significant differences. This finding suggests that a potential mechanism regarding the development of WMH may be attributable to the gut microbiome, either directly or indirectly. Further study regarding the association between cerebral SVD and the gut microbiome is warranted.
Our study has several strengths. First, we systematically assessed the cognitive functions of patients, using a comprehensive geriatric assessment in the setting of the memory clinic. These steps have provided detailed analyses of cognitive function. Second, we found a close and strong association between the gut microbiome and MCI, identified by multivariable analyses and graphical modelling, compared with the relationships between the other risk factors and MCI. Applying graphical modelling has strengthened our findings. Third, our comprehensive assessment regarding the gut microbiome and MCI may fill the knowledge gap regarding the mechanisms that connect cognitive decline with the gut microbiome. Finally, because we have established a new relationship and have widened the knowledge of such associations with regard to MCI, our findings may contribute to a better understanding and increased attention being paid to the associations between the gut microbiome and cognitive functions.
Nonetheless, this study has several limitations. A causal relationship between the gut microbiome and MCI could not be established because of the cross-sectional study design. The small number of patients renders our www.nature.com/scientificreports www.nature.com/scientificreports/ study at risk of being statistically underpowered. The unequal numbers of patients with MCI and those with NC may also be a potential limitation. Selection bias may exist because this was a single hospital-based cohort. Furthermore, potentially confounding factors may exist because the gut microbiome is affected by diet 20, 21 and the presence of complications, such as blood pressure variability and cardiovascular disease 13 . In particular, a recent study 21 suggests that the modified Mediterranean-ketogenic diet can modulate the gut microbiome and metabolites in association with improved biomarkers regarding Alzheimer's disease. Likewise, we plan to assess the nutritional status including the diet pattern in the future study because the Japanese diet pattern can alter the intestinal bacteria and have beneficial effects on humans 20 .
Assessments of the amyloid-β precursor protein may be useful because this factor suggests inflammatory endothelial dysfunction and the risk of cognitive impairment 22 . The specific mechanism through which the microbiome affects cognitive decline has not yet been clarified. Rather than identifying the roles of specific bacteria, the functional analysis of the gut microbiome as one integrated organ may be more practically useful. Our data indicate both accelerating (in the present study) and decelerating (in a previously published study 5 ) effects of Bacteroides on cognitive decline. However, this relationship may be attributable to unidentified taxa (indicated by 'other') and/or metabolites, which may depend on the intraintestinal environment. Next-generation sequencing technologies could be useful for identifying the specific genera or species of microbes that are collectively categorized as 'other' bacteria by the T-RFLP method.
To date, various risk factors for cognitive impairment have been proposed, such as aging, education years, hypertension, diabetes mellitus, and social factors 1 ; however, the human gut microbiome has not previously been mentioned as a risk factor. Our findings add the gut microbiome as a new risk factor for cognitive impairment. More importantly, controlling the gut microbiome may represent a possible method for the prevention and intervention of cognitive impairment.
Although this sub-analysis study contains a small number of patients and our analysis is preliminary, our findings provide supporting evidence for a relationship between the gut microbiome and cognitive impairment. Longitudinal assessments of the gut microbiome using next-generation sequencing technology, assessments of the various metabolites produced by the gut microbiome, and assessments of diet patterns should be investigated in future studies to clarify the underlying mechanism that connects the gut microbiome with cognitive function.
conclusions
We showed that components of the gut microbiome, in particular Bacteroides, may be associated with the presence of MCI in patients without dementia. We speculate that some gut microbiome metabolites could affect cognitive functions through a microbiome-gut-brain axis. Further studies are warranted to examine such relationships.
Methods
Study design. This study was a sub-analysis of our previously published, single-centre observational study (Gimlet study) 5 . The aim of this study was to investigate the association between the gut microbiome and MCI in patients without dementia. This study complied with the Declaration of Helsinki and was approved by the Institutional Review Board at the National Center for Geriatrics and Gerontology (No. 1191). Informed consent was obtained from all patients and their families before participation in this study. The Gimlet study is registered with the UMIN Clinical Trials Registry (UMIN000031851). Detailed information has been provided in the supplementary file and in the previous report 5 .
Subjects.
Patients were eligible for the Gimlet study if they met the following criteria: (1) were able to undergo a brain MRI; (2) provided informed consent in writing; (3) provided informed consent for the NCGG Biobank to store their clinical data, blood, and faecal samples; and (4) were accompanied by a study partner who could assess the patient's condition. Patients were excluded if they met the following criteria: (1) were unable to undergo an MRI examination or the MRI scan could not be evaluated because of movement; (2) had local lesions, such as cerebral infarctions, that were detected by MRI before enrolment and that could significantly affect cognitive function; (3) had a history of a major psychological disorders or current, serious or unstable alcohol or drug abuse; (4) had ≤6 years of education; (5) had a history of cancer of the digestive tract; or (6) were judged by an investigator to be ineligible to participate as a study subject (e.g., recent use of antibiotics, brain tumour, encephalitis/meningitis, normal pressure hydrocephalus, Huntington's disease). Patients were also excluded from this sub-analysis if they met the following criteria: (1) had dementia; or (2) were unable to provide sufficient faecal samples to facilitate the analysis of metabolites both now and in the future.
Baseline assessment. All participants underwent a comprehensive geriatric assessment 23 using the following: (1) demographic characteristics; (2) risk factors, such as hypertension, dyslipidaemia, diabetes mellitus, ischaemic heart disease, chronic kidney disease, smoking habits, or a history of stroke and alcohol consumption; (3) basic and instrumental ADL scales, assessed using the Barthel Index 24 and Lawton and Brody scale 25 ; (4) global cognitive function, assessed using the MMSE 26 and CDR 27 ; (5) neuropsychological testing, using the ADAS-cog 28 , RCPM 29 , FAB 30 , and LM-WMSR 31 ; (6) laboratory variables, including ApoE ε4 as a risk factor for AD; (7) ankle brachial index and pulse wave velocity, as indicators of arteriosclerosis 32 and the 'impact' of pulse 33 ; (8) brain imaging, such as MRI and SPECT; (9) an assessment of other factors, such as the presence of frailty 34 and subjective hearing loss; and (10) an assessment of social and lifestyle factors, e.g., using the Mini-Nutritional Assessment-Short Form (MNA-SF) to assess nutritional status 35 . Clinical samples and data were provided by the NCGG Biobank, which collects clinical data for research.
